摘要
Glioma, as the most common and aggressive malignant central nervous system （CNS） tumor with generally poor prognosis, has been attracting much attention in the last decade [1]. Temozolomide was firstly available in the United States in 1999 as a chemotherapy drug for treating brain cancers and remains as the first-line treatment for glioma. The World Health Organization （WHO） classified glioma into four main grades according to the degree of malignancy in 2007, which were updated in 2016 with the introduction of significant molecular alternations. Also in 2016, the Chinese Glioma Cooperative Group （CGCG） published the first guideline for adult diffuse gliomas [2], representing the only national consensus for the diagnosis and treatment of adult gliomas up till nOW.
Glioma, as the most common and aggressive malignant central nervous system （CNS） tumor with generally poor prognosis, has been attracting much attention in the last decade [1]. Temozolomide was firstly available in the United States in 1999 as a chemotherapy drug for treating brain cancers and remains as the first-line treatment for glioma. The World Health Organization （WHO） classified glioma into four main grades according to the degree of malignancy in 2007, which were updated in 2016 with the introduction of significant molecular alternations. Also in 2016, the Chinese Glioma Cooperative Group （CGCG） published the first guideline for adult diffuse gliomas [2], representing the only national consensus for the diagnosis and treatment of adult gliomas up till nOW.
